The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma
Open accessAbstract
BACKGROUND: Meningiomas are the most common primary intracranial tumor in adults. Identification of SMO and AKT1 mutations in meningiomas has raised the possibility of targeted therapies for some patients. The frequency of such mutations in clinical cohorts and the presence of other actionable mutations in meningiomas are important to define. METHODS: We used high-resolution array-comparative genomic hybridization to prospectively characterize copy-number changes in 150 meningiomas and then characterized these samples for mutations in AKT1, KLF4, NF2, PIK3CA, SMO, and TRAF7. RESULTS: Similar to prior reports, we identified AKT1 and SMO mutations in a subset of non-NF2-mutant meningiomas (ie, ∼9% and ∼6%, respectively). Notably, we detected oncogenic mutations in PIK3CA in ∼7% of non-NF2-mutant meningiomas. AKT1, SMO, and PIK3CA mutations were mutually exclusive. AKT1, KLF4, and PIK3CA mutations often co-occurred with mutations in TRAF7. PIK3CA-mutant meningiomas showed limited chromosomal instability and were enriched in the skull base. CONCLUSION: This work identifies PI3K signaling as an important target for precision medicine trials in meningioma patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Trofatter, J. (1993) · Cell · doi:10.1016/0092-8674(93)90406-g · Cited by 1,403
Epidemiology and etiology of meningioma
Wiemels, J., Wrensch, M., & Claus, E. B. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0386-3 · Cited by 1,226
Genomic Analysis of Non- NF2 Meningiomas Reveals Mutations in TRAF7 , KLF4 , AKT1 , and SMO
Clark, V. E., Erson-Omay, E. Z., Serin, A., Yin, J., Cotney, J., Özduman, K., Avşar, T., Li, J., Murray, P. B., Henegariu, O., et al. (2013) · Science · doi:10.1126/science.1233009 · Cited by 912
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
Brastianos, P. K., Horowitz, P. M., Santagata, S., Jones, R. T., McKenna, A., Getz, G., Ligon, K. L., Palescandolo, E., Van Hummelen, P., Ducar, M. D., et al. (2013) · Nature Genetics · doi:10.1038/ng.2526 · Cited by 651
Self-citationEvidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas
Ruttledge, M. H., Sarrazin, J., Rangaratnam, S., Phelan, C. M., Twist, E. C., Merel, P., Delattre, O., Thomas, G. D., Nordenskjöld, M., Collins, V. P., et al. (1994) · Nature Genetics · doi:10.1038/ng0294-180 · Cited by 573
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
Brastianos, P. K., Taylor-Weiner, A., Manley, P. E., Jones, R. T., Dias-Santagata, D., Thorner, A. R., Lawrence, M. S., Rodriguez, F. J., Bernardo, L. A., Schubert, L., et al. (2014) · Nature Genetics · doi:10.1038/ng.2868 · Cited by 521
Self-citationJanku, F., Wheler, J. J., Westin, S. N., Moulder, S. L., Naing, A., Tsimberidou, A. M., Fu, S., Falchook, G. S., Hong, D. S., Garrido-Laguna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1196 · Cited by 447
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Janku, F., Tsimberidou, A. M., Garrido-Laguna, I., Wang, X., Luthra, R., Hong, D. S., Naing, A., Falchook, G. S., Moroney, J. W., Piha-Paul, S. A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0994 · Cited by 331
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma
Kaley, T. J., Wen, P., Schiff, D., Ligon, K., Haidar, S., Karimi, S., Lassman, A. B., Nolan, C. P., DeAngelis, L. M., Gavrilovic, I., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou148 · Cited by 294
Self-citation
Cited by
EANO guidelines for the diagnosis and treatment of meningiomas
Goldbrunner, R., Minniti, G., Preusser, M., Jenkinson, M. D., Sallabanda, K., Houdart, E., von Deimling, A., Stavrinou, P., Lefranc, F., Lund-Johansen, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30321-7 · Cited by 854
Estrogen and progesterone therapy and meningiomas
Hage, M., Plesa, O., Lemaire, I., & Raffin Sanson, M. L. (2022) · Endocrinology · doi:10.1210/endocr/bqab259 · Cited by 63
Metadata
- Authors
- Abedalthagafi, M., Bi, W. L., Aizer, A. A., Merrill, P. H., Brewster, R., Agarwalla, P. K., Listewnik, M. L., Dias-Santagata, D., Thorner, A. R., Van Hummelen, P., Brastianos, P. K., Reardon, D. A., Wen, P. Y., Al-Mefty, O., Ramkissoon, S. H., Folkerth, R. D., Ligon, K. L., Ligon, A. H., Alexander, B. M., Dunn, I. F., Beroukhim, R., & Santagata, S.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-01-28
- Volume
- 18
- Issue
- 5
- Pages
- 649-655
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2328930886
- Cited by
- 293
- References
- 28
- FWCI
- 23.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. https://app.cochat.ai/papers/10.1093/neuonc/nov316
- The paper
- Abedalthagafi, M., Bi, W. L., Aizer, A. A., Merrill, P. H., Brewster, R., Agarwalla, P. K., Listewnik, M. L., Dias-Santagata, D., Thorner, A. R., Van Hummelen, P., Brastianos, P. K., Reardon, D. A., Wen, P. Y., Al-Mefty, O., Ramkissoon, S. H., Folkerth, R. D., Ligon, K. L., Ligon, A. H., Alexander, B. M., . . . Santagata, S. (2016). Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro-Oncology. https://doi.org/10.1093/neuonc/nov316
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
